HitGen Inc. and the Biotech Sector: A Financial Overview
Market Activity and Biotech Stocks
On September 4, 2025, the biotech sector saw significant activity, with innovative drug concept stocks experiencing heightened trading. Among the notable performers, 济民健康 (Jimin Health) reached its daily price limit, while 键凯科技 (Jian Kai Technology) surged over 10%. Other companies such as 悦康药业 (Yu Kang Pharmaceutical), 诺思格 (Nostig), 前沿生物 (Qianyan Biology), 信立泰 (Xinli Tai), and 成都先导 (Chengdu Xiandao) also saw substantial gains.
Shenzhen Stock Exchange Performance
The Shenzhen Stock Exchange’s ChiNext Board, which lists many innovative and high-growth companies, experienced a decline on September 3, 2025. The ChiNext 50 Index fell by 1.64%, closing at 1306.48 points. The day’s trading volume was 50.41 billion shares, with a total transaction value of 23.56 billion CNY. The weighted average turnover rate was 2.70%.
Among the 146 stocks that closed higher, nine stocks saw gains exceeding 10%, while 14 stocks rose between 5% and 10%. Conversely, 440 stocks closed lower, with six stocks experiencing declines of over 10%.
Top Turnover Stocks
The stock with the highest turnover rate was 影石创新 (Yingshi Innovation), which closed down 2.26% with a turnover rate of 18.84% and a transaction value of 20.47 billion CNY. Following closely was 赛诺医疗 (Saino Medical), which rose 12.67% with a turnover rate of 18.03% and a transaction value of 25.70 billion CNY. Other notable stocks with high turnover rates included 成都华微 (Chengdu Huawei), 利扬芯片 (Liyang Chip), and 先锋精科 (Xianfeng Jingke).
Sector Performance
In terms of sector performance, the electronics industry had the highest number of stocks with turnover rates exceeding 5%, with 45 stocks listed. The power equipment and computer sectors followed, with 15 and 14 stocks, respectively.
Capital Flows
Among high-turnover stocks, 47 stocks received net inflows of main force capital. The largest net inflows were seen in 源杰科技 (Yuanjie Technology), 赛诺医疗 (Saino Medical), and 阿特斯 (Ates), with net inflows of 2.92 billion CNY, 2.05 billion CNY, and 1.48 billion CNY, respectively. In contrast, stocks like 东芯股份 (Dongxin), 上纬新材 (Shangwei Xincai), and 云天励飞 (Yuntian Liefly) experienced significant net outflows.
Leveraged Capital Movements
Among high-turnover stocks, 128 stocks received net purchases of leveraged capital. The largest increases in financing balances over the past five days were seen in 百济神州 (Baizhi Shenzhou), 华虹公司 (Huahong), and 上纬新材 (Shangwei Xincai), with increases of 6.73 billion CNY, 4.51 billion CNY, and 3.22 billion CNY, respectively. Conversely, stocks like 中船特气 (Zhongchuan Teqi), 磁谷科技 (Cigu Technology), and 麒麟信安 (Qilin Xiansheng) saw significant decreases in financing balances.
Recombinant Protein Concept
On September 3, 2025, the recombinant protein concept saw a slight increase of 0.03%, ranking fifth in concept board gains. Stocks like 成都先导 (Chengdu Xiandao), 百普赛斯 (Bai Pu Sai Si), and 热景生物 (Re Jing Biology) led the gains, while 赛升药业 (Saiseng Pharmaceutical), *ST万方 (ST Wanfang), and 汇宇制药 (Huiyu Pharmaceutical) experienced declines.
Capital Inflows
The recombinant protein concept received net outflows of 0.86 billion CNY, with 15 stocks experiencing net inflows. The largest net inflows were seen in 德展健康 (Dezhan Health), 一品红 (Yipinhong), and 成都先导 (Chengdu Xiandao), with inflows of 1.24 billion CNY, 9647.02 million CNY, and 7921.58 million CNY, respectively.
HitGen Inc. Overview
HitGen Inc., a Chinese company listed on the Shanghai Stock Exchange, closed at 25.32 CNY on September 1, 2025. The company’s 52-week high was 27.58 CNY, and its 52-week low was 8.35 CNY. With a market capitalization of 101,452,174,777 CNY and a price-to-earnings ratio of 111.33, HitGen Inc. remains a significant player in the biotech sector.